Why Treating All Childhood Obesity the Same Way Is Failing Patients

Nearly 1 in 5 children in the US is living with obesity, and without a meaningful shift in how clinicians identify and treat the condition, projections suggest the global burden will only worsen in the decades ahead.

A narrative review published in the International Journal of Molecular Sciences synthesized current evidence on the diagnosis and management of childhood obesity, arguing that a phenotype-driven, patient-centered framework—one that accounts for genetic, behavioral, environmental, and metabolic contributors—is essential for meaningful clinical progress.

The Status Quo Isn't Working

The review was prompted by a rapidly evolving treatment landscape and a persistent gap between emerging pharmacologic evidence and clinical practice. In the US, the prevalence of obesity among children and adolescents aged 2 to 19 years reached 19.7%—approximately 14.7 million young people—by 2020, up from 5% in the late 1970s. A meta-analysis of more than 2000 studies cited in the review found a 1.5-fold increase in childhood obesity prevalence between 2012 and 2023, with the steepest rises seen among children aged 6 to 12 years, males, those attending private schools, and those born to mothers with overweight or obesity. The World Obesity Federation has projected that the global prevalence among children and adolescents aged 5 to 19 years will reach 254 million by 2030.²

Despite this trajectory, management approaches have historically defaulted to lifestyle modification alone—an intervention the authors noted has demonstrated limited long-term efficacy, particularly in children with genetic forms of the disease.¹

Not All Childhood Obesity Is Created Equal

A central contribution of the review was a proposed stepwise diagnostic framework organized around 4 major phenotypes: polygenic, monogenic, syndromic, and endocrine. Polygenic obesity, the most common form, arises from interactions among lifestyle exposures, epigenetic changes, and hundreds of genetic variants with modest individual effect sizes. Twin studies have estimated the heritability of obesity at 47% to 90%.

Monogenic obesity—characterized by severe, early-onset disease typically presenting before age 5—accounts for approximately 5% of severe obesity cases and most often involves pathogenic variants in genes regulating the hypothalamic leptin-melanocortin pathway, including MC4R, LEP, LEPR, POMC, and PCSK1. Syndromic obesity, such as that seen in Prader-Willi syndrome and Bardet-Biedl syndrome, typically presents alongside dysmorphic features and developmental delay.

The authors emphasized that identifying the underlying subtype has direct therapeutic implications, noting that "ensuring equitable access and sustained implementation in real-world settings will be key" to translating precision approaches into practice.

New Drugs, Real Results—With Caveats

The review highlighted a growing pharmacologic armamentarium for adolescents aged 12 and older with a body mass index at or above the 95th percentile. The 2023 American Academy of Pediatrics clinical practice guideline recommended that clinicians offer weight loss medications alongside lifestyle intervention for this population.

Among glucagon-like peptide-1 receptor agonists, the STEP TEENS trial (NCT04102189) demonstrated that once-weekly subcutaneous semaglutide 2.4 mg produced a mean body mass index (BMI) reduction of approximately 16% over 68 weeks in adolescents with obesity. A separate randomized controlled trial found that liraglutide 3.0 mg daily produced significantly greater BMI reductions and higher proportions achieving clinically meaningful weight loss thresholds compared with placebo in adolescents aged 12 to 17 years. Both agents carried risks of gastrointestinal adverse effects, and the authors cautioned that weight regain was commonly observed after discontinuation.

For children with monogenic obesity due to LEPR, POMC, PCSK1, or Bardet-Biedl syndrome variants, setmelanotide—an MC4R agonist approved for use in patients aged 6 years and older—demonstrated meaningful reductions in hunger and body weight, with 80% of participants in a phase 3 POMC deficiency trial achieving at least 10% weight loss at approximately 1 year.

What the Long-Term Surgical Data Show

Bariatric surgery was characterized as a safe and effective option for adolescents with severe obesity and related comorbidities, with long-term data from the Teen Longitudinal Assessment of Bariatric Surgery study demonstrating durable weight loss and high rates of comorbidity remission at 5-year follow-up.³ Laparoscopic sleeve gastrectomy was identified as the most common procedure in adolescents, in part due to a lower risk of micronutrient deficiency relative to Roux-en-Y gastric bypass.¹

What the Evidence Cannot Tell Us

As a narrative review, the paper was subject to selection bias and did not employ systematic search methodology or formal quality appraisal of included studies. The authors also acknowledged that long-term efficacy data for newer pharmacotherapies remain limited, that polygenic risk scores perform variably across ancestry groups, and that access to precision treatments such as metreleptin and setmelanotide is constrained by cost and availability in many regions.

References

1. Gad H, Dauleh H, Mohammed I, Malik RA, Hussain K. Management of childhood obesity. Int J Mol Sci. 2026;27(8):3528. doi:10.3390/ijms27083528

2. Global Atlas on Childhood Obesity. World Obesity Federation. Accessed May 28, 2026. https://www.worldobesity.org/membersarea/global-atlas-on-childhood-obesity

3. Inge TH, Zeller M, Harmon C, et al. Teen-Longitudinal Assessment of Bariatric Surgery: methodological features of the first prospective multicenter study of adolescent bariatric surgery. J Pediatr Surg. 2007;42:1969–1971. doi:10.1016/j.jpedsurg.2007.08.010